Vincerx Pharma enters at-the-market equity offering deal

CAR-T Digest - August 2020

22 Jan 2025: Vincerx Pharma enters at-the-market equity offering deal

Vincerx partnered with H.C. Wainwright & Co. for a $30 million at-the-market equity offering
Recently, it terminated sales agreement with Leerink Partners, approved a reverse stock split, and received a Nasdaq extension to meet bid price by May 2025
It reported positive Phase 1 results for VIP943 ADC in hematologic malignancies
Extended cash runway into early 2025, revised guidance, and Leerink Partners lowered price target from $4.00 to $2.00, maintaining an outperform rating
In equity offering aimed at stabilizing capital structure after a 76.57% decline in stock value, addressing operational and funding needs